Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
(Efgartigimod alfa + hyaluronidase (human recombinant)) by Argenx for Graves' Ophthalmopathy: Likelihood of Approval
(Efgartigimod alfa + hyaluronidase (human recombinant)) is under clinical development by Argenx and currently in Phase III for Graves' Ophthalmopathy....